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1115-68 Predictors of Vascular Complications in Patients 
Undergoing Percutaneous Coronary Intervention and 
Treated With Vascular Closure Devices
Raj Goswami, John G. McGinnity, Arthur L. Riba, Cecelia K. Montoye, Dean E. Smith, 
Julius Gardin, Michael J. O'Donnell, Anthony C. DeFranco, David Share, Mauro 
Moscucci, For The Blue Cross Blue Shield of Michigan Cardiovascular Consortium 
(BMC2), University of Michigan, Ann Arbor, MI
Objective. The objective of our study was to identify clinical predictors of vascular com-
plications in patients undergoing contemporary percutaneous coronary interventions and
treated with vascular closure devices, VCDs (Vasoseal, Angioseal, Perclose, or others).
Methods. Clinical, procedural and outcome data on 27,202 consecutive PCIs were pro-
spectively collected between April 2001 and May 2003 in a consortium of 16 hospitals in
Michigan. Independent predictors of vascular complications (VC) were identified using
multivariate logistic regression analysis.
Results. 6270 patients received a vascular closure device. Vasoseal was used in 2.7%,
Angioseal in 41.9%, Perclose in 54.7% and other devices in 0.7%. The overall vascular
complication rate in this group was 3.3%. There was a non-significant trend toward an
increased incidence of VC in patients treated with Vasoseal (4.38%) when compared
with patients treated with Angioseal (2.98%) or Perclose (3.46%). Of 28 clinical and treat-
ment variables including type of vascular closure device, multivariate analysis identified
advanced age, female sex, acute myocardial infarction, cardiac arrest, cardiogenic shock
and glycoprotein IIb/IIIa receptor blocker use as independent predictors of VC (all
p<0.05).
Conclusions. Baseline clinical characteristics identify patients at increased risk of vas-
cular complications following use of VCD. The occurrence of vascular complications in
these patients appears to be independent of the type of VCD.
1115-69 Lower Hematocrit Is Associated With Worse Health 
Status in Patients With Heart Failure
Avinash Khanna, Mikhail Kosoborod, Philip Jones, Harlan M. Krumholz, John A. Spertus, 
Mid America Heart Institute and University of Missouri at Kansas City, Kansas City, MO, 
Yale University, New Haven, CT
Background: Anemia is a potentially modifiable comorbid condition in patients with heart
failure (HF). Its effect on health status has not been well defined. We tested the hypothe-
sis that lower hematocrit levels in patients with post-Myocardial Infarction (MI) HF are
associated with worse quality of life as measured by the Kansas City Cardiomyopathy
Questionnaire (KCCQ).
Methods: The EPHESUS trial enrolled 6632 patients with post-MI HF, of which 1578 par-
ticipated in the quality of life substudy. 3-month KCCQ scores were compared across the
following ranges of hematocrit: <0.33, 0.33-0.35, 0.36-0.38, 0.39-0.41, 0.42-0.44 and
>0.45. This time was selected to reflect a chronic HF state following patients’ MI.
Results: Compared with non-anemic patients, anemic patients (hematocrit <0.39) were
more likely to be female (46% vs 20%, p<0.001), older (68±24 vs 62±23, p<0.0001), dia-
betic (34% vs 23%, p<0.0001) and to have a higher serum creatinine (1.3 ± 1.0 vs 1.1±
0.6, p<0.001). Lower hematocrits were associated with worse (lower) KCCQ scores.
After adjusting for baseline demographic and clinical differences, a highly significant rela-
tionship between hematocrit and KCCQ summary scores was observed (Adjusted
Means shown in Figure, p<0.0001).
Conclusions: Lower hematocrits are associated with worse quality of life in HF patients,
even after controlling for a range of potentially confounding factors. Further investigation
of the health status benefits from correcting anemia in HF patients appears warranted. 
1115-70 Effect of Obesity on Long-Term Survival Following 
Percutaneous Coronary Intervention
Kenneth C. Wen, Timothy A. Sanborn, Warren Sherman, David L. Brown, Beth Israel 
Medical Center, New York, NY
Background: Obesity is a powerful risk factor for the development of coronary artery dis-
ease. Paradoxically, recent studies have suggested that obesity actually protects against
mortality following percutaneous coronary intervention (PCI).We sought to determine the
impact of obesity on long-term survival following PCI using a contemporary database.
Methods: The study population consisted of 4284 consecutive patients undergoing PCI
from January 1, 1998 to October 1, 1999 at 3 hospitals in New York City. Patients were
then divided into two groups, obese patients with body mass index (BMI) > 30 (n=1,410)
and non-obese patients with BMI < 30 (n=2,874). Primary endpoint was all-cause mortal-
ity following the index PCI. Mean follow-up was 3 years. Results: Obese patients were
younger (60 vs. 65 years, P<0.001) and more frequently female (36% vs. 29%, P<0.001).
Mean BMI was 34.7 in the obese patients and 25.6 in the non-obese patients (P<0.001).
Hypertension (74% vs. 68%, P<0.001) and diabetes (33% vs. 24%, P<0.001) were more
common in obese patients while peripheral vascular disease (6.1% vs. 8.7%, P<0.001)
and prior bypass surgery (14% vs. 19%, P<0.001) were less common. Presentation with
myocardial infarction (9.4% vs. 11%, P=NS) and unstable angina (41% vs. 43%, P=NS)
did not differ between obese and non-obese patients. Single-vessel coronary disease
was more common in obese patients (53% vs. 46%, P<0.001) and mean ejection frac-
tions were slightly greater (51% vs. 50%, P=0.04). Stent use did not differ between
groups. Angiographic success was slightly reduced in obese patients (96% vs. 97%,
P=0.06). In-hospital major adverse cardiac events did not differ between obese and non-
obese patients. Out-of-hospital death was 7.2% for obese patients and 10.3% in the non-
obese (P=0.001). After adjustment for differences in baseline characteristics, obesity was
found not to be associated with an increased hazard of long-term mortality (Hazard
Ratio, 0.992, 95% Confidence Interval, 0.784 – 1.254, P=0.945). Conclusion: Obesity
does not appear to protect patients from long-term mortality following PCI. However, nei-
ther does it increase the hazard of 3-year mortality after adjustment for other co-morbidi-
ties.
1115-71 Depression Is Strongly Associated With Worse Health 
Status in Patients With Myocardial Infarction 
Complicated by Heart Failure: Data From the EPHESUS 
Trial
John S. Rumsfeld, Mary A. Whooley, Philip Jones, Mark D. Sullivan, Pamela N. Peterson, 
William S. Weintraub, Bertram Pitt, John A. Spertus, Denver VA Medical Center, Denver, 
CO, University of Missouri-Kansas City, Kansas City, MO
Background: We evaluated the relationship between depression and health status in
patients with acute MI complicated by heart failure.
Methods: Patients in the EPHESUS trail (NEJM, 2003) completed a Medical Outcomes
Study-Depression (MOS-D) questionnaire at baseline and Kansas City Cardiomyopathy
Questionnaire (KCCQ) at baseline,1,3,6, and 12 months. The KCCQ measures heart-
failure health status including symptoms, physical function, and quality of life. The KCCQ
summary score has range 0-100; higher scores = better health status; 5 points = clini-
cally important score difference. We used repeated measures and multivariable regres-
sion to evaluate the association between depressive symptoms (MOS-D score > 0.06)
and KCCQ summary scores.
Results: 93/423 patients (22%) had significant depressive symptoms. Depressed
patients had markedly lower KCCQ scores during follow-up (Figure). After risk adjust-
ment, depression remained significantly associated with worse baseline (p<0.001) and
12-month (p<0.001) KCCQ scores - on average, depressed patients had 8.8 point lower
KCCQ scores at baseline and 13.4 point lower KCCQ scores at 12-months. Depressive
symptoms were the strongest predictor of health status in the multivariable models.
Conclusion: In patients with AMI complicated by heart failure, depressive symptoms are
1
Treatment Angioplasty Clinica
l
Surgery p
Period pre 12m 24m pre 12m 24m pre 12m 24m
Physical Functioning 59 72,8 72,44 50 66,2 62,50 47 73,5 73,69 0,002
Role Physical 34 52,6 51,13 23 39,8 38,49 21 48,2 50,19 0,018
General Health 65 63,8 66,09 63 60,8 62,40 63 64,4 68,19 0,018
Mental Health 66 74,6 42,59 63 70,4 42,47 64 74 41,14 NS
Vitality 64 72,2 46,13 56 61,6 41,94 56 73,8 45,27 0,02
Role Emotional 52 67,1 69,92 50 64,9 64,91 46 68,9 68,72 NS
Social Functioning 58 70 86,28 57 62,7 80,35 53 66,9 87,60 0,02
Bodly Pain 63 75,4 70,50 62 70,1 67,30 57 76,8 73,55 NS
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strongly associated with worse health status. Depression interventions should be evalu-
ated in this population with the goal of improving cardiac symptoms and quality of life.
1115-72 Aggressive Treatment of Atrial Fibrillation Reduces 
Stoke Following Cardiac Surgery
Robert W. Murdock, Jeffrey Kaliebe, Nathan Hayes, Mary Jo Hessert, Chad Landwehr, 
Audrey Schlund, Karen J. Olson, Fernando Riveron, John Johnkoski, Ronald Miles, 
David K. Murdock, CaRE Foundation, Inc, Wausau, WI, Community Health Care/Wausau 
Heart Institute, Wausau, WI
Background: Stroke is an occasional complication of cardiac surgery. Most strokes
associated with cardiac surgery are postoperative strokes (POS) and occur after the
patient appears to have recovered from anesthesia uneventfully. Postoperative atrial
fibrillation (POAF) is a frequent complication of cardiac surgery. POAF is a risk factor for
POS. It is not known whether treating or preventing POAF will decrease POS. Purpose:
Determine if POS can be reduced by aggressive treatment of POAF. Methods: Historical
review of all patients undergoing cardiac surgery for coronary artery bypass graft (CABG)
and/or cardiac valve surgery at our institution between 1/1/93 to 6/30/2003. Group (A)
patients (1/1/93 to 6/30/1999) served as control before aggressive POAF treatment pro-
tocol instituted. Group (B) patients (7/1/1999 to 6/30/2003) were treated with measures
to prevent POAF (beta blockers, magnesium supplementation, pre and post-operative
amiodarone therapy). Antiarrhythmic agents were administered if POAF occurred. DC
cardioversion was performed if POAF persisted > 24 hours. If POAF persisted despite
cardioversion and antiarrhythmics, anticoagulant therapy was instituted with heparin.
Patients were then placed on warfarin until normal sinus rhythm persisted. Results: A
=2084 patients and B =2212 patients were similar with respect to age (65.2 vs 66.3), %
male sex (68.1 vs 68.6), ejection fraction (53.8 vs 52.7), and prior atrial fibrillation (9.4%
vs 9.0%). More B patients had valve surgery (19.8% vs 13.7% p<0.01), were hyperten-
sive (68.9% vs 57.9%, p<0.01), and had their CABG done “off pump” (57.7% vs 1.8%
p<0.0001). The incidence of POAF was 32.7% in A and 20.3% in B, (p<0.001). In valve
patients, the incidence of POAF was 40.6% in A and 24.9% in B, (p<0.01). The incidence
of POS was 2.35% in A and 0.8% in B, (p<0. 001). In group B CABG patients, the inci-
dence of POS and POAF was similar regardless of the “on pump”/ “off pump” status.
Conclusion: Aggressive measures to prevent and treat POAF were associated with a
significant decrease in the occurrence of stroke following cardiac surgery.
1115-73 Sinus Bradycardia Is a Poor-Prognostic Indicator in 
Cocaine-Induced Acute Coronary Syndromes
Paul H. Nguyen, Annette Quick, Richard Kettlekamp, John House, John Spertus, Mukesh 
Garg, Truman Medical Center, Kansas City, MO, Mid-America Heart Institute, Kansas 
City, MO
Background: Cocaine is a complex drug and its use can cause lethal cardiovascular
events, including myocardial infarction (MI) and sudden cardiac death due to ventricular
arrhythmias. Isolated case reports have implicated cocaine-induced bradyarrhythmias as
the cause of syncope. However, the adverse effects of cocaine-induced sinus bradycar-
dia have not been studied. The objective of this retrospective study is to examine the
prognostic relationship of cocaine-induced acute coronary syndrome (ACS) and sinus
bradycardia.
Methods: A total of 1,199 patients meeting prospectively defined and retrospectively val-
idated ACS criteria were entered into a registry at two inner-city hospitals. 58 (5%)
patients used cocaine either by self-report or positive urine drug screen. The analysis of
the relationship of sinus bradycardia (Heart Rate < 60 bpm) to rates of Rehospitalization,
Major Adverse Cardiac Events (MACE-myocardial infarction, stroke, congestive heart
failure, and death) and the degree of Coronary Artery Disease (CAD) was performed
among the 58 patients with cocaine-related ACS.
Results: Of the 58 patients, 12 (21%) patients were admitted with sinus bradycardia as
their initial rhythm. Patients' characteristics and treatment as defined by age, gender,
hypertension, smoking, left ventricular function, and beta blocker use between those with
and without bradycardia were similar. Rehospitalization was more common in patients
with bradycardia (83.3% vs. 47.8%; p=.028). The incidence of occlusive CAD was also
higher among patients with sinus bradycardia (83.3%) vs. patients without sinus brady-
cardia (45%) p=0.099. The percentage of MACE among cocaine-related ACS patients
with sinus bradycardia trended to be higher (25%) vs. non-sinus bradycardia cocaine-
related ACS patients (13%) p=.308.
Conclusion: Patients admitted with cocaine-induced ACS and bradycardia have higher
rate of Rehospitalization and are more likely to have occlusive coronary artery disease
and trend towards having more MACE. The underlying pathophysiology for this intriguing
finding needs to be explored further.
1115-74 Screening for Asymptomatic Coronary Artery Disease 
in the Potential Renal Transplant Recipient
Jay S. Varanasi, Fred Costello, Gail E. Tudor, Alan L. Hinderliter, Walter A. Tan, Mauricio 
G. Cohen, E. Magnus Ohman, Venu Menon, University of North Carolina, Chapel Hill, 
NC
Background: Patients with end stage renal disease (ESRD) are at high risk for CAD.
Screening has been recommended for asymptomatic ESRD patients awaiting transplant.
A prior meta-analysis has shown that positive (+) nuclear perfusion scans (NPS) corre-
late with increased risk of cardiac death in this population. Methods: We reviewed 128
consecutive asymptomatic patients with ESRD awaiting renal transplant. All subjects
underwent NPS for the evaluation of occult epicardial CAD (90% adenosine Sestamibi).
We excluded subjects with h/o prior MI, known CAD, PVD, CABG or PCI. We compared
baseline characteristics of patients with and without (+) NPS. A (+) NPS was defined as a
reversible perfusion defect or a fixed defect with an underlying wall motion abnormality.
Results: The mean age was 52 yrs and 56% were male. The primary etiology of ESRD
was diabetes mellitus (DM) in 39%, hypertension (Htn) in 21% and miscellaneous in 40%
. Overall, 31% (40/128) of subjects had positive NPS. Subjects with (+) NPS were similar
to their counterparts with respect to age (53 vs. 50 yrs), African American race (68 vs.
68%), smoking (45 vs. 41%), LVH on ECG (38 vs. 41%), h/o CVA (10 vs. 8%), hyperlipi-
demia (33 vs. 33%), and need for dialysis (90 vs. 88%) with all p=NS. The gated LVEF
was lower in subjects with (+) NPS (50 vs. 57%, p = 0.0009). Rates of test positivity with
NPS were 44%, 36% and 24% in the group of subjects with Htn nephropathy, DM nephr-
opathy and miscellaneous groups respectively (p= 0.05). Both DM (p= 0.07) and Htn
nephropathy subjects (p= 0.02) had significantly higher rates of NPS than their counter-
parts with renal disease of miscellaneous etiology. Of the 19 patients with Htn/DM
referred for cath, only 5 had a (+) angiogram (> 50% stenosis). Conclusions: The rate of
(+) NPS in asymptomatic ESRD patients is high (31%) and is related to the underlying
renal etiology. Subjects with DM or Htn nephropathy have significantly higher rates of (+)
NPS. Patients with (+) NPS have a significantly lower LVEF; however, (+) NPS did not
correlate with angiography. The previously reported increased risk of death with (+) NPS
may not be related to epicardial CAD, but instead to decreased LVEF; alternative non-
invasive modalities should be considered.
1115-75 Prognostic Impact of Depression Following Myocardial 
Infarction: A Meta-Analysis
Joost van Melle, Peter de Jonge, Titia Spijkerman, Jan GP Tijssen, Johan Ormel, Dirk J. 
van Veldhuisen, Maarten P. van den Berg, University Hospital Groningen, Groningen, 
The Netherlands, Academic Medical Center, Amsterdam, The Netherlands
Background- To assess the impact of depression following myocardial infarction (MI) on
cardiovascular prognosis.
Methods- Meta-analysis of references derived from MEDLINE, EMBASE and PSYCINFO
(1975-January 2002) combined with cross-referencing, without language restrictions. We
selected prospective studies which determined the impact of depression on the cardio-
vascular outcome of MI patients, defined as mortality and cardiovascular events within 2
years from index MI. Depression had to be assessed within 3 months after MI using
established psychiatric instruments.
Results- 17 papers met our selection criteria. These studies described follow up (on aver-
age 12.8 months) of 3803 MI patients (12 cohorts). Post MI depression was significantly
associated with all-cause mortality (OR fixed 2.58, 95% CI 1.71-3.89; p<0.00001) and
cardiac mortality (OR fixed 2.50, 95% CI 1.71-3.68; p<0.00001). Depressive MI patients
were also at risk for new cardiovascular events (OR fixed 2.12, 95% CI 1.52-2.95;
p<0.00001). Secondary analyses showed no significant effects of follow up duration (0-6
months or longer) or assessment of depression (self-report questionnaire versus inter-
view). However, the year of data collection (before or after 1992) significantly influenced
the effect of depression on mortality (p=0.05), with stronger associations found in the
earlier studies.
Conclusion- Post MI depression is associated with a 2-2.5 fold increased risk of impaired
cardiovascular outcome. The impact of depression on cardiac mortality or all-cause mor-
tality was more pronounced in the older studies (before 1992) than in the more recent
studies.
1115-76 Effect of Body Mass Index on Long-Term Mortality in 
Patients Undergoing Coronary Artery Bypass Graft
Emir Veledar, Jerome Abramson, Zefeng Zhang, Viola Vaccarino, Edward Chen, William 
Weintraub, Emory University, Atlanta, GA
Background: It is unclear whether obesity predicts long term mortality after CABG. We
sought to quantify the effect of BMI on long term mortality in a large data base of patients
undergoing CABG.
Methods: We studied CABG patients from 1970 to 1991 in the Emory University Health-
care System and compared mortality risk between 5 BMI groups, adjusting for baseline
demographic and clinical characteristics using Cox proportional hazards models. Mean
follow up was 9.3 years.
Results: Of 15,096 patients discharged alive, 3.2% were underweight (BMI <20), 34.9%
had a normal weight (BMI 20 to 25), 45.2 % were overweight (BMI 25.1 to 30), 13.4%
obese (BMI 30.1 to 35), and 3.3% severely obese (BMI >35). In unadjusted analysis, only
underweight patients were at increased mortality risk compared with normal-weight
patients. In adjusted analysis, underweight, obese and severely obese patients showed
an increased mortality risk, while being overweight was not associated with higher mor-
tality compared with normal-weight patients. 
